IceCure Medical Ltd.
7 Ha'Eshel St.
Southern Industrial Park
20 articles with IceCure Medical Ltd.
Positive Interim Results from IceCure Medical's ICE3 Clinical Trial for Breast Cancer Treatment by Freezing with the ProSense® Cryoablation System Presented at the 2021 ASBrS Meeting
IceCure Medical Ltd., developer of the minimally invasive cryoablation ProSense® System that destroys tumors by freezing, announced interim results from the Company's ICE3 clinical trial for cryoablation of small low-risk breast cancer tumors.
IceCure Medical Ltd. (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation cryoablation technology that destroys tumors by freezing without the need for surgery, today announced that the Company will present at H.C. Wainwright Global Life Sciences Conference, which is being held virtually from March 9-10, 202
IceCure Signs Exclusive Distribution Agreement with Rise General Trading, LCC, Expanding Market Reach Across the Middle East
Three-Year Agreement Launches Distribution of IceCure's ProSense® Cryoablation System in the United Arab Emirates and Persian Gulf States
Upon closing, the company to meet Nasdaq listing requirements without the need to effect a concurrent public offering; funds to enable the company to expand the commercialization of its products in existing and new markets and accelerate development of new products in the coming year
Expanded Agreement Builds from the Success of its Current Joint Activities in Japan and Singapore, to Bring its Cryoablation Products to Benefit More Patients in Asia
IceCure Expands Strategic Collaboration with Terumo: New Commercial Distribution Agreement Potentially Valued at over $7.0 Million
Thailand, with a Population of 70 million People, Joins Other Significant Territories Japan and Singapore That will Benefit From IceCure's Cryoablation Products
IceCure Raises NIS 20.7 Million in Equity Share Offering; Received Oversubscribed Demand of NIS 24 Million
Recently Reported Preliminary First-Half 2020 Sales Were x3 Higher than Same Period in 2019, Demonstrating Significant Growth as Cryoablation Technology Continues to Gain Global Awareness
New Indian regulatory approval received for its cryoablation technology to destroy tumors in extensive indications, including for breast, lung, bone and kidney cancer
IceCure Enters German Cryoablation Oncology Market; Inks Exclusive Distribution Agreement With MTS Medical Technology
New German Territory Follows Accelerating Global Expansion with Orders in Singapore and Thailand This Month for Its Freezing Technology to Destroy Tumors
New Territory in Singapore with Global Medical Leader, Terumo, Marks Successful Partnership Progress in Executing Milestone Distribution Agreement
IceCure Receives FDA Clearance for Expanded Indications of Cryoablation Technology and Regulatory Approval of New MultiSense System; Plans to Increase U.S. Presence and Operations
Following the additional U.S. Food and Drug Administration clearance for its Cryoablation Technology, IceCure Medical Ltd., an Israeli medical device company, developers of a non-surgical Liquid Nitrogen cryoablation technology to destroy benign and cancerous tumors by freezing, plans to significantly extend its U.S. operations in target markets for indications with existing CPT codes and reimbursement.
IceCure Medical Ltd. (TASE: ICCM), developer of the next generation cryoablation technology to treat malignant and benign tumors by freezing without the need for surgery, announced today an exclusive distribution agreement with leading global medical company, Terumo Corporation (Tokyo: 4543, TRUMY: OTC US)
IceCure Medical Presents Promising Results from First-ever Interventional Radiology Study With Its Next Generation Liquid Nitrogen (LN2) Cryoablation System, ProSense™
Data presented at the European Association of Urology showed the ProSense™ system at 1-year follow-up was safe, effective and without serious adverse events for treating small kidney tumors
IceCure Medical Ltd. Release: National Multi-Center Clinical Trial Of Non-Surgical Breast Cancer Treatment Enrolls First Patients
IceCure Medical Ltd. Announces Treatment of First Breast Cancer Patient Using Its IceSense3 Cryoablation System at John Wayne Cancer Institute
IceCure Medical Ltd. Enters a New High-Potential Market: the Company Received $100K-Order for Cryoablation Consoles and Probes to be Used in a Clinical Study for the Treatment of Lung Cancer
Arbel Medical has Completed a $4.5 million Round of Capital Raising led by Giza Venture Capital Fund